Detail akcie Biocryst Pharm online

Business Summary: BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Its portfolio also includes navenibart, which is a late-stage, long-acting plasma kallikrein inhibitor. It has also obtained an early-stage program for atopic dermatitis, STAR0310.
Financial Summary: BRIEF: For the three months ended 31 March 2026, BioCryst Pharmaceuticals Inc revenues increased 7% to $156.4M. Net loss totaled $721.8M vs. income of $32K. Revenues reflect Product sales increase of 5% to $151.4M, Collaborative and other research increase from $1.7M to $5M. Net loss reflects Research and development increase of 62% to $60.3M (expense), Selling, General and administrative increase of 15% to $94.6M (expense).